Left Ventricular Hypertrophy in CKD Patients

January 24, 2026 updated by: Khaled Mohamed Mohamedin, Sohag University

Prevalence of Left Ventricular Hypertrophy (LVH) in CKD Patients and Effect of Erythropoietin Therapy

The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.

The main question it aims to answer is:

Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The prevalence of LVH in CKD patients has been reported to range from 40% to 75%, depending on disease stage, blood pressure control, and diagnostic methodology. LVH typically develops early and worsens with CKD progression, reflecting the close interplay between renal dysfunction and cardiac remodeling.

Anemia is a prominent non-hemodynamic contributor to LVH in CKD. Reduced erythropoietin (EPO) production by the damaged kidneys, together with iron deficiency and chronic inflammation, leads to decreased oxygen delivery, compensatory cardiac output elevation, and subsequent ventricular hypertrophy.

Given the strong association between CKD, anemia, and cardiovascular remodeling, investigating the prevalence of LVH and the effect of erythropoietin therapy on left ventricular mass among CKD patients can provide critical insights into optimizing cardiovascular risk management in this high-risk group.

this study will be conducted to :

  1. To determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital.
  2. To assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients.

A total of 100 CKD patients will be included.

  • Phase I : All CKD patients will undergo echocardiographic evaluation to determine the prevalence of LVH.
  • Phase II : Among anemic CKD patients with LVH receiving erythropoietin therapy , will be followed for 6 months

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Marwa Z Elsayed, MD
  • Phone Number: +201007100970

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

study population is adults age (18-75)years, diagnosed with CKD stage 3-5 .

Description

Inclusion Criteria:

  • Adults (≥18 years) diagnosed with CKD stages 3-5.
  • Stable clinical condition for ≥3 months.
  • Anemia (Hb <10 g/dL) for cohort phase.
  • Willingness to participate and provide informed consent.

Exclusion Criteria:

  • Valvular or ischemic heart disease.
  • Uncontrolled hypertension (BP >180/110 mmHg).
  • Acute coronary syndrome or decompensated heart failure in the past 3 months.
  • Malignancy or active infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in LVMI following erythropoietin therapy in anemic CKD patients.
Time Frame: - baseline transthoracic echocardiography will be performed for all group study.
- baseline transthoracic echocardiography will be performed for all group study.

Secondary Outcome Measures

Outcome Measure
Time Frame
Association between hemoglobin level and LVMI.
Time Frame: 6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.
6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Study Chair: Amal Kh Ahmed, MD, Sohag university- faculty of medicine - internal medicine department

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 15, 2026

Primary Completion (Estimated)

June 15, 2026

Study Completion (Estimated)

July 15, 2026

Study Registration Dates

First Submitted

December 30, 2025

First Submitted That Met QC Criteria

January 24, 2026

First Posted (Actual)

February 2, 2026

Study Record Updates

Last Update Posted (Actual)

February 2, 2026

Last Update Submitted That Met QC Criteria

January 24, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med--25-11-7MS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Left Ventricular Hypertrophy

Clinical Trials on transthoracic echocardiography

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe